A8468612
Zoledronic Acid , ≥99% , 118072-93-8
Synonym(s):
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid) monohydrate;P,P′-[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid monohydrate;Zoledronate monohydrate;Zoledronic acid monohydrate
CAS NO.：118072-93-8
Empirical Formula: C5H10N2O7P2
Molecular Weight: 272.09
MDL number: MFCD00867791
EINECS: 1806241-263-5
| Pack Size | Price | Stock | Quantity |
| 25MG | RMB47.20 | In Stock |
|
| 100MG | RMB103.20 | In Stock |
|
| 1G | RMB463.20 | In Stock |
|
| 5G | RMB1519.20 | In Stock |
|
| 25G | RMB4799.20 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 193-2040C (dec) |
| Boiling point: | 764.0±70.0 °C(Predicted) |
| Density | 2.13±0.1 g/cm3(Predicted) |
| storage temp. | Sealed in dry,Room Temperature |
| solubility | Soluble in Water (up to 2 mg/ml). |
| form | solid |
| pka | 1.41±0.10(Predicted) |
| color | White or off-white |
| Stability: | Stable for 2 years from date of purchase as supplied. Solutions in distilled water may be stored at -20° for up to 2 months. |
Description and Uses
Zoledronic acid is a white, crystalline powder that is available in vials for reconstitution for IV infusion over at least 15 minutes. It does not undergo metabolic transformation and does not inhibit CYP450 enzymes. Clearance of this agent is dependent on the patient's creatinine clearance, not on dose. Serum creatinine levels should be evaluated before every treatment. Zolendronic acid is contraindicated in patients with severe renal impairment.
bone resorption inhibitor
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H317-H319 |
| Precautionary statements | P261-P272-P280-P302+P352-P333+P313-P321-P363-P501-P264-P280-P305+P351+P338-P337+P313P |
| Hazard Codes | Xi |
| Risk Statements | 21/22-36/37/38 |
| Safety Statements | 24/25-36/37/39 |
| HS Code | 2933399090 |
